Thirteen New Biospecimen Suppliers Added to iSpecimen’s Proprietary Provider Network

Rhea-AI Summary

iSpecimen Inc. has added thirteen new biospecimen suppliers to its proprietary Marketplace®, expanding the breadth and depth of biospecimen offerings for researchers. The expanded network provides greater access to human biosamples in various disease categories. The new suppliers offer a wide range of sample types, including banked and prospectively collected samples. Notably, one supplier offers access to over 640,000 patients across five sites, while another specializes in isolated immune cells and banked antigen-specific T cells. Additionally, iSpecimen added a supplier focused on frozen clinical-grade cord blood and another exclusively sourcing biospecimens from African patient pools to promote diversity in research.

Network’s Expansion Across the U.S. and Europe Aims to Advance Translational Genomics Research

LEXINGTON, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that the Company has added thirteen new biospecimen suppliers to iSpecimen’s proprietary Marketplace^® throughout the first half of 2023. The addition of these new sample providers increases the breadth and depth of biospecimen offerings for researchers, including varying sample types and formats that are both banked and prospectively collected.

iSpecimen’s expanded network will provide researchers with even greater access to human biosamples within various cancer and hematology, cardiovascular, autoimmune, neurological, endocrine, metabolic and infectious disease categories. Additional specimen capabilities include those for environmental and food-based allergies, genitourinary disorders, pediatric conditions, pregnancy including normal, high risk, and fetal abnormalities, pulmonary and respiratory tract disorders, skin and connective tissue disorders, and much more, to be integrated into the platform. Notably, one sample provider offers access to over 640,000 patients across five sites focused on prospective collections for a wide array of disease indications. Another provider specializes in highly characterized isolated immune cells from healthy donors, as well as banked antigen-specific T cells. iSpecimen also added a new supplier focused on frozen clinical-grade cord blood, showcasing the comprehensive offerings available within the global network.

Additionally, to support the Company’s goal of advancing research among diverse patient populations, one of the new suppliers exclusively sources biospecimens from African patient pools to help improve health outcomes and advance translational and genomics research for diseases that are prevalent in African communities.

“As the industry’s global research and development activities continue to evolve in complexity, it is becoming increasingly important for researchers to have access to a wide range of biospecimens,” said Tracy Curley, iSpecimen’s CEO. “To address this growing need, the Company focused on efficiently adding more specimen providers to its network that can also contribute more thoughtful recommendations regarding specimen requirements, which can ultimately support and expedite the drug discovery process. The iSpecimen Marketplace’s expanded network also helps to promote diversity among patient populations, ensuring that no group goes underrepresented when it comes to finding treatments for diseases.”

About iSpecimen
iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Phil Carlson / Erika Kay
iSpecimen@kcsa.com

Media Contacts
KCSA Strategic Communications
Raquel Cona / Shana Marino
iSpecimen@kcsa.com

FAQ

What is the name of the company in the press release?

The company mentioned in the press release is iSpecimen Inc.

What does iSpecimen do?

iSpecimen is an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers.

What did iSpecimen announce?

iSpecimen announced the addition of thirteen new biospecimen suppliers to its proprietary Marketplace®.

What does the expansion of iSpecimen's network mean for researchers?

The expansion provides researchers with greater access to human biosamples in various disease categories, including cancer, hematology, cardiovascular, autoimmune, neurological, endocrine, metabolic, and infectious diseases.

What types of sample offerings are available through iSpecimen's expanded network?

The expanded network offers varying sample types, including banked and prospectively collected samples. It includes offerings for environmental and food-based allergies, genitourinary disorders, pediatric conditions, pregnancy, pulmonary and respiratory tract disorders, skin and connective tissue disorders, and more.

What are some notable additions to iSpecimen's network?

One supplier offers access to over 640,000 patients across five sites, while another specializes in isolated immune cells and banked antigen-specific T cells. iSpecimen also added a supplier focused on frozen clinical-grade cord blood. Additionally, one supplier exclusively sources biospecimens from African patient pools to promote diversity in research.

What is the goal of iSpecimen's expanded network?

The goal is to provide researchers with a wide range of biospecimens to support and expedite the drug discovery process. It also aims to promote diversity among patient populations to ensure no group goes underrepresented in finding treatments for diseases.